Abstract
Background Terazosin, doxazosin, and alfuzosin (Tz/Dz/Az) are α-1 adrenergic receptor antagonists that also bind to and activate a key ATP-producing enzyme in glycolysis. Recent work has suggested a potentially neuroprotective effect of use of Tz/Dz/Az in Parkinson’s disease in both animal and human studies. We investigated neuroprotective effects of Tz/Dz/Az in a closely related disease, dementia with Lewy bodies (DLB).
Methods We used a new user active comparator design in the merative Marketscan database to identify men with no history of DLB who were newly started on Tz/Dz/Az or two comparator medications. Our comparator medications were other drugs commonly used to treat benign prostatic hyperplasia that do not increase ATP: the α-1 adrenergic receptor antagonist tamsulosin or 5α-reductase inhibitors (5ARI). We matched the cohorts on propensity scores and duration of follow-up. We followed the matched cohorts forward to estimate the hazard of developing DLB.
Results Men who were newly started on Tz/Dz/Az had lower hazard of developing DLB then matched men taking tamsulosin (HR=0.60, p<0.001) or 5ARI (HR=0.73, p=0.012) while the hazard in men taking tamsulosin was similar to that of men taking 5ARI (HR=1.17, p=0.12). These results were robust to several sensitivity analyses.
Conclusions These data demonstrate that Tz/Dz/Az in decreases the risk of DLB. When combined with the literature of Tz/Dz/Az on PD, our findings suggest that glycolysis-enhancing drugs may be broadly protective in neurodegenerative synucleinopathies. These observational associations must be further evaluated for causality in future randomized trials.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Access to the Marketscan database was provided by the University of Iowa. Dr. Simmering was supported by a faculty fellowship at the Iowa Neuroscience Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of the University of Iowa waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: Access to the Marketscan database was provided by the University of Iowa. Dr. Simmering was supported by a faculty fellowship at the Iowa Neuroscience Institute.
Data Availability
The merative Marketscan database is used under license from merative that prohibits redistribution of the data. Interested users may contact merative to obtain a license for their use.
